Related Experiment Videos
The inhibitory effects of bryostatin 1 administration on the growth of rabbit papillomas
J M Bodily1, D J Hoopes, B L Roeder
1Department of Microbiology, Brigham Young University, Provo, UT 84602-5133, USA.
Abstract:
Bryostatin 1 is a protein kinase C modulator that shows antineoplastic activity in a variety of tumor systems. This study examined the effects of bryostatin 1 administration on papilloma growth in rabbits. Investigations of optimal route, dose, and schedule were performed. Several groups of rabbits were inoculated with cottontail rabbit papillomavirus (CRPV) DNA. Bryostatin 1 was administered i.v., both daily and weekly, and intralesionally both weekly and bi-weekly. Intralesionally dosed papillomas were examined histologically for immune cell infiltration. In weekly and daily i.v. trials, 2.5 and 1.0 microg/kg, respectively, showed the greatest overall reduction in tumor size. Bryostatin 1 administered intralesionally also slowed papilloma growth. Treated lesions had significantly higher numbers of heterophils and eosinophils.
Insights
Bryostatin 1, a protein kinase C modulator, effectively reduced papilloma tumor size in rabbits. The study explored optimal administration routes and doses, noting increased immune cell infiltration in treated lesions.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Bryostatin 1 is a protein kinase C modulator with demonstrated antineoplastic properties.
- Papillomas induced by cottontail rabbit papillomavirus (CRPV) serve as a model for studying tumor growth and treatment efficacy.
Purpose of the Study:
- To investigate the efficacy of Bryostatin 1 in reducing papilloma growth in rabbits.
- To determine the optimal administration route (intravenous vs. intralesional), dose, and schedule for Bryostatin 1 treatment.
- To evaluate the histological effects of Bryostatin 1 on papilloma lesions, specifically immune cell infiltration.
Main Methods:
- Rabbits were inoculated with cottontail rabbit papillomavirus (CRPV) DNA to induce papillomas.
- Bryostatin 1 was administered via intravenous (IV) and intralesional routes with varying daily, weekly, and bi-weekly schedules.
- Tumor size reduction was measured, and treated papilloma lesions were histologically examined for immune cell infiltration.
Main Results:
- Intravenous administration of Bryostatin 1 at 2.5 microg/kg weekly and 1.0 microg/kg daily resulted in the greatest reduction in tumor size.
- Intralesional administration of Bryostatin 1 also demonstrated a significant inhibitory effect on papilloma growth.
- Histological analysis revealed significantly higher numbers of heterophils and eosinophils in Bryostatin 1-treated lesions compared to controls.
Conclusions:
- Bryostatin 1 exhibits significant antineoplastic activity against rabbit papillomas, supporting its potential as a therapeutic agent.
- Both intravenous and intralesional administration routes show promise, with specific doses and schedules influencing efficacy.
- Bryostatin 1 treatment is associated with an increased infiltration of heterophils and eosinophils, suggesting an immunomodulatory effect contributing to tumor reduction.